Viewing StudyNCT06417814

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-19 @ 5:34 PM
Last Modification Date: 2024-10-26 @ 3:29 PM
Study NCT ID: NCT06417814
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-07-11
First Post: 2024-05-13
Brief Title: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: AstraZeneca
Organization: AstraZeneca
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Metastatic Non-small Cell Lung Cancer
Keywords:
Name View
Cisplatin View
Epidermal growth factor receptor gene mutation View
Standard of Care View
Locally advanced carcinoma View
Metastatic carcinoma View
Non-small cell lung cancer View
Dato-dxd View
Datopotamab deruxtecan View
Osimertinib View
Tagrisso View
Pemetrexed View
Carboplatin View